Allergic sensitization plays a significant role in the pathogenesis of asthma in many patients. Immunotherapy of allergic asthma is controversial. Large-scale trials in patients aged 6 to 76 years with moderate-to-severe allergic asthma have shown that anti-IgE (omalizumab) therapy is safe and effective in reducing corticosteroid dosages and preventing exacerbations.